TAS-102 plus radiation for older adults with esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests adding an oral chemotherapy drug (TAS-102) to radiation therapy for older patients (65–85) with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps control the cancer without causing too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 65 and 85 years old.
- You must have newly diagnosed esophageal squamous cell carcinoma that has not spread to distant organs (except certain nearby lymph nodes).
- You must be in fairly good physical condition (able to do all daily activities without help or with minimal help).
- You cannot have had any prior chemotherapy, radiation, or surgery for this cancer.
- Your lungs, kidneys, liver, and blood counts must be within acceptable ranges.
- You must not have a history of certain lung diseases or severe heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.